Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Tempero

Showing results (41-50 of 50) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 50 results.
Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery|May 25, 2010
Lymphatic malformations: review of current treatmentJonathan A Perkins, Scott C Manning, Richard M Tempero, et al.
The American Journal of Pathology|February 9, 2008
Integrin alpha1beta1 regulates matrix metalloproteinases via P38 mitogen-activated protein kinase in mesangial cells: implications for Alport syndromeDominic Cosgrove, Daniel T Meehan, Duane Delimont, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 1, 1997
Molecular adjuvant effects of a conformationally biased agonist of human C5a anaphylatoxinR M Tempero, M A Hollingsworth, M D Burdick, et al.
Leukemia & Lymphoma|May 16, 2000
Phase I/II trial of multiple dose 131Iodine-MAb LL2 (CD22) in patients with recurrent non-Hodgkin's lymphomaJ M Vose, D Colcher, L Gobar, et al.
ESMO Open|December 25, 2021
The impact of COVID-19 on cancer care and oncology clinical research: an experts' perspectiveC Sessa, J Cortes, P Conte, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2000
Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancerS J Knox, M L Goris, M Tempero, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 4, 2021
Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE studyM Tempero, D-Y Oh, J Tabernero, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 27, 2008
The diagnosis and management of rectal cancer: expert discussion and recommendations derived from the 9th World Congress on Gastrointestinal Cancer, Barcelona, 2007E Van Cutsem, M Dicato, K Haustermans, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 10, 2007
The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006C Verslype, E Van Cutsem, M Dicato, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 9, 2022
Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic cancer groupT Seufferlein, W Uhl, M Kornmann, et al.
Pageof 5

Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
Otolaryngology--Head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery|May 25, 2010
Lymphatic malformations: review of current treatmentJonathan A Perkins, Scott C Manning, Richard M Tempero, et al.
The American Journal of Pathology|February 9, 2008
Integrin alpha1beta1 regulates matrix metalloproteinases via P38 mitogen-activated protein kinase in mesangial cells: implications for Alport syndromeDominic Cosgrove, Daniel T Meehan, Duane Delimont, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 1, 1997
Molecular adjuvant effects of a conformationally biased agonist of human C5a anaphylatoxinR M Tempero, M A Hollingsworth, M D Burdick, et al.
Leukemia & Lymphoma|May 16, 2000
Phase I/II trial of multiple dose 131Iodine-MAb LL2 (CD22) in patients with recurrent non-Hodgkin's lymphomaJ M Vose, D Colcher, L Gobar, et al.
ESMO Open|December 25, 2021
The impact of COVID-19 on cancer care and oncology clinical research: an experts' perspectiveC Sessa, J Cortes, P Conte, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2000
Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancerS J Knox, M L Goris, M Tempero, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 4, 2021
Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE studyM Tempero, D-Y Oh, J Tabernero, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 27, 2008
The diagnosis and management of rectal cancer: expert discussion and recommendations derived from the 9th World Congress on Gastrointestinal Cancer, Barcelona, 2007E Van Cutsem, M Dicato, K Haustermans, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 10, 2007
The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006C Verslype, E Van Cutsem, M Dicato, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 9, 2022
Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic cancer groupT Seufferlein, W Uhl, M Kornmann, et al.
Pageof 5